Journal of Hepatology
Volume 52, Issue 2 , Pages 252-257 , February 2010

Risk of HCC: Genetic heterogeneity and complex genetics

References 

  1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16
  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917
  3. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002;11:369–376
  4. Franceschi S, Montella M, Polesel J, La Vecchia C, Crispo A, Dal Maso L, et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev. 2006;15:683–689
  5. IARC . Hepatitis viruses. IARC Monogr Eval Carcinog Risks Hum. 1994;59:1–255
  6. El Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160:3227–3230
  7. Ogimoto I, Shibata A, Kurozawa Y, Nose T, Yoshimura T, Suzuki H, et al. Risk of death due to hepatocellular carcinoma among drinkers and ex-drinkers. Univariate analysis of JACC study data. Kurume Med J. 2004;51:59–70
  8. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer. 2000;85:498–502
  9. Baan R, Straif K, Grosse Y, Secretan B, el Ghissassi F, Bouvard V, et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007;8:292–293
  10. IARC . Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum. 2002;82:171–300
  11. IARC . Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1–1438
  12. Dragani TA, Canzian F, Manenti G, Pierotti MA. Hepatocarcinogenesis: a polygenic model of inherited predisposition to cancer. Tumori. 1996;82:1–5
  13. Feo F, De Miglio MR, Simile MM, Muroni MR, Calvisi DF, Frau M, et al. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta. 2006;1765:126–147
  14. Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol. 2008;103:2136–2141
  15. Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma?. Eur J Gastroenterol Hepatol. 1996;8:989–994
  16. Janecke AR, Mayatepek E, Utermann G. Molecular genetics of type 1 glycogen storage disease. Mol Genet Metab. 2001;73:117–125
  17. Lee PJ. Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr. 2002;161(Suppl. 1):S46–S49
  18. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002;161(Suppl. 1):S20–S34
  19. Franco LM, Krishnamurthy V, Bali D, Weinstein DA, Arn P, Clary B, et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis. 2005;28:153–162
  20. Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr. 1993;152(Suppl. 1):S63–S70
  21. Alexander J, Kowdley KV. HFE-associated hereditary hemochromatosis. Genet Med. 2009;11:307–313
  22. Pietrangelo A. Hereditary hemochromatosis–a new look at an old disease. N Engl J Med. 2004;350:2383–2397
  23. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. Hepatology. 2008;48:991–1001
  24. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology. 2003;125:1733–1741
  25. Haddow JE, Palomaki GE, McClain M, Craig W. Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention. J Med Screen. 2003;10:11–13
  26. Seth AK, Badminton MN, Mirza D, Russell S, Elias E. Liver transplantation for porphyria: who, when, and how?. Liver Transpl. 2007;13:1219–1227
  27. Ulbrichova D, Hrdinka M, Saudek V, Martasek P. Acute intermittent porphyria – impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties. FEBS J. 2009;276:2106–2115
  28. Ostrowski J, Kostrzewska E, Michalak T, Zawirska B, Medrzejewski W, Gregor A. Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias. Gastroenterology. 1983;85:1131–1137
  29. Andant C, Puy H, Bogard C, Faivre J, Soule JC, Nordmann Y, et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol. 2000;32:933–939
  30. Badenas C, To-Figueras J, Phillips JD, Warby CA, Munoz C, Herrero C. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet. 2009;75:346–353
  31. Aarsand AK, Boman H, Sandberg S. Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clin Chem. 2009;55:795–803
  32. Fracanzani AL, Taioli E, Sampietro M, Fatta E, Bertelli C, Fiorelli G, et al. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol. 2001;35:498–503
  33. Solis JA, Betancor P, Campos R, Enriquez de Salamanca RE, Rojo P, Marin I, et al. Association of porphyria cutanea tarda and primary liver cancer: report of ten cases. J Dermatol. 1982;9:131–137
  34. Salata H, Cortes JM, Enriquez DS, Oliva H, Castro A, Kusak E, et al. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. J Hepatol. 1985;1:477–487
  35. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol. 2003;39:620–627
  36. Scott CR. The genetic tyrosinemias. Am J Med Genet C Semin Med Genet. 2006;142C:121–126
  37. Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr. 1976;88:434–438
  38. Beland K, Lapierre P, Alvarez F. Influence of genes, sex, age and environment on the onset of autoimmune hepatitis. World J Gastroenterol. 2009;15:1025–1034
  39. Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Bjornsson E, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol. 2009;50:388–393
  40. Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology. 2008;48:146–156
  41. El Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369–380
  42. Florez JC. Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008. J Clin Endocrinol Metab. 2008;93:4633–4642
  43. Salanti G, Southam L, Altshuler D, Ardlie K, Barroso I, Boehnke M, et al. Underlying genetic models of inheritance in established type 2 diabetes associations. Am J Epidemiol. 2009;170:537–545
  44. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88:1472–1477
  45. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36:1206–1213
  46. Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A. Cancer and diabetes – a follow-up study of two population-based cohorts of diabetic patients. J Intern Med. 1997;241:471–475
  47. Hemminki K, Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. Gut. 2003;52:592–596
  48. Shen FM, Lee MK, Gong HM, Cai XQ, King MC. Complex segregation analysis of primary hepatocellular carcinoma in Chinese families: interaction of inherited susceptibility and hepatitis B viral infection. Am J Hum Genet. 1991;49:88–93
  49. Shih WL, Yu MW, Chen PJ, Yeh SH, Lo MT, Chang HC, et al. Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. Oncogene. 2006;25:3219–3224
  50. Shih WL, Yu MW, Chen PJ, Wu TW, Lin CL, Liu CJ, et al. Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study. Eur J Hum Genet. 2009;17:1250–1259
  51. Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999–2002). Thyroid. 2007;17:1211–1223
  52. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, et al. Association between hypothyroidism and hepatocellular carcinoma: a case–control study in the United States. Hepatology. 2009;49:1563–1570
  53. Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?. J Clin Gastroenterol. 2003;37:340–343
  54. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(Suppl. 19):89–95
  55. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24:248–254
  56. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007;11:119–132
  57. Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, Desantis D, Hsiao G, et al. Diet-induced hepatocellular carcinoma in genetically-predisposed mice. Hum Mol Genet. 2009;18:2975–2988
  58. Wild CP, Turner PC. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis. 2002;17:471–481
  59. Wojnowski L, Turner PC, Pedersen B, Hustert E, Brockmoller J, Mendy M, et al. Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics. 2004;14:691–700
  60. Chen X, Wang H, Xie W, Liang R, Wei Z, Zhi L, et al. Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case–control study in a high-risk region of China. Pharmacogenet Genomics. 2006;16:219–227
  61. White DL, Li D, Nurgalieva Z, El Serag HB. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol. 2008;167:377–389
  62. Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol. 2000;53:88–93
  63. Ding J, Li S, Wu J, Gao C, Zhou J, Cao H, et al. Alcohol dehydrogenase-2 and aldehyde dehydrogenase-2 genotypes, alcohol drinking and the risk of primary hepatocellular carcinoma in a Chinese population. Asian Pac J Cancer Prev. 2008;9:31–35
  64. Homann N, Stickel F, Konig IR, Jacobs A, Junghanns K, Benesova M, et al. Alcohol dehydrogenase 1C∗1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer. 2006;118:1998–2002
  65. Nahon P, Sutton A, Rufat P, Ziol M, Akouche H, Laguillier C, et al. Myeloperoxidase and SOD2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology. 2009;50:1484–1493
  66. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576
  67. La Vecchia C, Negri E, Cavalieri dL, Franceschi S. Liver cirrhosis and the risk of primary liver cancer. Eur J Cancer Prev. 1998;7:315–320
  68. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. 2009;15:280–288
  69. Dragani TA, Manenti G, Della Porta G. Enhancing effects of carbon tetrachloride in mouse hepatocarcinogenesis. Cancer Lett. 1986;31:171–179
  70. Gariboldi M, Manenti G, Canzian F, Falvella FS, Pierotti MA, Della Porta G, et al. Chromosome mapping of murine susceptibility loci to liver carcinogenesis. Cancer Res. 1993;53:209–211
  71. Manenti G, Binelli G, Gariboldi M, Canzian F, De Gregorio L, Falvella FS, et al. Multiple loci affect genetic predisposition to hepatocarcinogenesis in mice. Genomics. 1994;23:118–124
  72. Manenti G, Galvan A, Falvella FS, Pascale RM, Spada E, Milani S, et al. Genetic control of resistance to hepatocarcinogenesis by the mouse Hpcr3 locus. Hepatology. 2008;48:617–623
  73. De Miglio MR, Canzian F, Pascale RM, Simile MM, Muroni MR, Calvisi D, et al. Identification of genetic loci controlling hepatocarcinogenesis on rat chromosomes 7 and 10. Cancer Res. 1999;59:4651–4657
  74. De Miglio MR, Pascale RM, Simile MM, Muroni MR, Virdis P, Kwong KM, et al. Polygenic control of hepatocarcinogenesis in Copenhagen x F344 rats. Int J Cancer. 2004;111:9–16

PII: S0168-8278(09)00743-0

doi: 10.1016/j.jhep.2009.11.015

Journal of Hepatology
Volume 52, Issue 2 , Pages 252-257 , February 2010

Article Tools

* Image Usage & Resolution